Infliximab- and methotrexate-resistant rebound of psoriasis after discontinuation of efalizumab (Raptiva® )
Authors:
- 31 July 2006
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 155 (4) , 846-847
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Cutaneous Adverse Events of Biological Therapy for Psoriasis: Review of the LiteratureDermatology, 2005
- Eczematous drug eruption after infliximabBritish Journal of Dermatology, 2004
- Efalizumab in the treatment of psoriasisDermatologic Therapy, 2004
- Atopic dermatitis-like eruption precipitated by infliximabJournal of the American Academy of Dermatology, 2003